ArticleJournal of the American Society of Cytopathology
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Article in Journal of the American Society of Cytopathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.Diagnostic cytopathology · 2022Pooled it
- Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusions.Cancer cytopathology · 2024Article
- Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer.Clinical and experimental medicine · 2024Review
- NKX2‑1 copy number alterations are associated with oncogenic, immunological and prognostic remodeling in non‑small cell lung cancer.Oncology letters · 2024Article
- Review
- A novel quantitative prognostic model for initially diagnosed non-small cell lung cancer with brain metastases.Cancer cell international · 2022Article
- The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.Journal of the Egyptian National Cancer Institute · 2022Article
- PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.International journal of molecular sciences · 2022Article
- Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- PD-L1 and beyond: Immuno-oncology in cytopathology.Cytopathology : official journal of the British Society for Clinical Cytology · 2021Review
- Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.Cancer cytopathology · 2021Article
- Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.Frontiers in oncology · 2021Review
- PD-L1 in Cytological Samples: A Review and a Practical Approach.Frontiers in medicine · 2021Review
- A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.Cancer cytopathology · 2020Article
- Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer.Translational lung cancer research · 2020Review
- Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.Virchows Archiv : an international journal of pathology · 2020Article
- Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.Therapeutic advances in medical oncology · 2020Article
- Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.Acta cytologica · 2020Article
- The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Immunocytochemistry for predictive biomarker testing in lung cancer cytology.Cancer cytopathology · 2019Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
introductionProgrammed death ligand 1 (PD-L1) testing of non-small cell lung cancer (NSCLC) specimens helps select patients most likely to respond to immune checkpoint inhibitors. PD-L1 immunohistochemical testing is approved for formalin-fixed, paraffin-embedded (FFPE) surgical pathology specimens; however, the testing performance on FFPE cytology cell block specimens is unknown. MATERIALS AND
methodsThe study is a retrospective cohort analysis of advanced stage NSCLC patients treated at our institution where tumor PD-L1 expression using the clone 22C3 pharmDx kit on the Dako Automated Link 48 platform was performed on either cytology cell block or surgical pathology specimens. Concomitant tumor mutation biomarkers were also collected, as well as tumor clinicopathologic characteristics and clinical outcome data following pembrolizumab treatment.
results232 patient tumor specimens were tested for PD-L1 expression (94 on cytology cell block and 138 on surgical pathology specimens). No significant differences in PD-L1 tumor proportion score (TPS) were observed between cytology and surgical pathology groups, with both patient cohorts containing ~35% of tumors showing TPS ≥50%. Although few in number, patients with PD-L1 TPS ≥50% based on cytology vs. surgical pathology who received treatment with pembrolizumab demonstrated similar response and disease control rates.
conclusionsIn this cohort of advanced NSCLC patients with standard of care PD-L1 testing performed on either FFPE cytology cell blocks or FFPE surgical pathology specimens, similar patterns were observed in population tumor PD-L1 expression patterns, concomitant driver mutations, and clinical response to palliative pembrolizumab in selected patients with TPS ≥50%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.